Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
Genta announces EMA Orphan Drug designation for tesetaxel

Genta announces EMA Orphan Drug designation for tesetaxel

CTTC, Spero enter sales agreement for Calmare medical devices

CTTC, Spero enter sales agreement for Calmare medical devices

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Researchers develop KU-32 drug to prevent diabetic peripheral neuropathy

Researchers develop KU-32 drug to prevent diabetic peripheral neuropathy

Mayo Clinic opens newly expanded neurophysiology laboratory at Florida campus

Mayo Clinic opens newly expanded neurophysiology laboratory at Florida campus

DARA BioSciences presents KRN5500 study results at World Congress on Pain

DARA BioSciences presents KRN5500 study results at World Congress on Pain

CTTC's Calmare therapy effective against pain associated with chemotherapy-induced peripheral neuropathy

CTTC's Calmare therapy effective against pain associated with chemotherapy-induced peripheral neuropathy

Study finds acupuncture can control side effects of cancer treatment

Study finds acupuncture can control side effects of cancer treatment

Researchers suggest Hsp70 can reverse Diabetic peripheral neuropathy

Researchers suggest Hsp70 can reverse Diabetic peripheral neuropathy

NeuroMetrix second-quarter total revenues decrease to $3.9 million

NeuroMetrix second-quarter total revenues decrease to $3.9 million

EpiCept second-quarter net loss decreases to $4.9 million

EpiCept second-quarter net loss decreases to $4.9 million

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

MRCC deploys CTT's Calmare Pain Therapy Treatment medical device

MRCC deploys CTT's Calmare Pain Therapy Treatment medical device

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Scientists develop new version of medication to relieve severe forms of pain

Scientists develop new version of medication to relieve severe forms of pain

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.